dc.contributor.author
Lewis, Richard
dc.contributor.author
Habringer, Stefan
dc.contributor.author
Kircher, Malte
dc.contributor.author
Hefter, Maike
dc.contributor.author
Peuker, Caroline Anna
dc.contributor.author
Werner, Rudolf
dc.contributor.author
Ademaj-Kospiri, Valëza
dc.contributor.author
Gäble, Alexander
dc.contributor.author
Weber, Wolfgang
dc.contributor.author
Wester, Hans-Jürgen
dc.contributor.author
Buck, Andreas
dc.contributor.author
Herhaus, Peter
dc.contributor.author
Lapa, Constantin
dc.contributor.author
Keller, Ulrich
dc.date.accessioned
2023-03-13T16:36:15Z
dc.date.available
2023-03-13T16:36:15Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/38350
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-38069
dc.description.abstract
Background: The chemokine receptor CXCR4 is frequently overexpressed and associated with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently, CXCR4 molecular imaging using the CXCR4-specific positron emission tomography (PET) tracer Pentixafor ([Ga-68]Pentixafor) has become a well-established method to non-invasively measure CXCR4 expression in vivo. In previous Pentixafor imaging studies, highly variable CXCR4 tracer uptake to the spleen was observed.
Results: We investigated the hypothesis that enhanced spleen [Ga-68]Pentixafor uptake and thus CXCR4 expression in patients with solid tumors would indicate an activated spleen state and/or an association with clinical and prognostic features and survival parameters. In this retrospective study, [Ga-68]Pentixafor-PET images and patient records of 145 solid tumor patients representing 27 cancer entities were investigated for an association of spleen [Ga-68]Pentixafor uptake and clinical characteristics and outcome. Based on this assessment, we did not observe differences in clinical outcomes, measured by progression-free survival, overall survival and remission status neither within the entire cohort nor within subgroups of adrenal cancer, desmoplastic small round cell tumor, neuroendocrine tumors, non-small cell lung cancer, small cell lung cancer and pancreatic adenocarcinoma patients. No tumor entity showed especially high levels of spleen [Ga-68]Pentixafor uptake compared to others or a control cohort. However, when investigating laboratory parameters, there was a positive correlation of high spleen [Ga-68]Pentixafor uptake with leukocyte and/or platelet counts in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer.
Conclusion: Spleen [Ga-68]Pentixafor uptake was not associated with stage of disease and clinical outcomes in solid tumor patients. We identified positively associated platelet and/or leukocyte counts with spleen [Ga-68]Pentixafor uptake in neuroendocrine tumors, non-small cell lung cancer and small cell lung cancer, suggesting that splenic CXCR4 expression could possibly play a role in systemic immunity/inflammation in some types of solid tumors or a subgroup of patients within solid tumor entities.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Solid tumors
en
dc.subject
Clinical studies
en
dc.subject
Retrospective studies
en
dc.subject
Molecular imaging
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
77
dcterms.bibliographicCitation.doi
10.1186/s13550-021-00822-6
dcterms.bibliographicCitation.journaltitle
EJNMMI Research
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
11
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34417915
dcterms.isPartOf.eissn
2191-219X